Health Catalyst, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 2, 2024, by Health Catalyst, Inc. (HCAT), a healthcare data analytics company. The report covers events occurring between November 2 and November 6, 2024, including the announcement of Q3 2024 financial results, a strategic acquisition, and a Board of Directors appointment.
Key Financial Metrics and Transactions
Specific revenue, profit, cash flow, and margin figures for the quarter ended September 30, 2024, are not detailed in the text of this 8-K; they are referenced in attached Exhibits 99.1 and 99.2. However, the filing discloses the following financial data points:
- Acquisition Price: Approximately $43 million for Intraprise Health, LLC.
- Stock Consideration: Approximately 2,200,490 shares of common stock valued at $8.18 per share.
- Related Party Revenue: The Queens Health System (QHS), a client of the newly appointed director, paid approximately $9.9 million in the nine months ended September 30, 2024, and $5.4 million in the fiscal year ended December 31, 2023.
- Director Compensation: New director Dr. Jill Hoggard Green will receive a pro-rated $45,000 annual cash retainer, a $7,500 committee retainer, and an initial $225,000 restricted stock unit award.
Material Changes and Corporate Actions
The filing reports three material developments:
- Acquisition of Intraprise Health: On November 5, 2024, the Company entered an agreement to acquire Intraprise Health, LLC. The deal is expected to close by the end of 2024, subject to customary conditions.
- Board Expansion: The Board expanded from seven to eight directors. Dr. Jill Hoggard Green was appointed effective December 1, 2024, to fill a newly created seat.
- Financial Results: The Company issued a press release on November 6, 2024, regarding its Q3 2024 results, though specific metrics are not included in this summary text.
Outlook, Risks, and Contingencies
Management provided forward-looking statements regarding the expected closing of the Intraprise acquisition and the anticipated benefits. The filing explicitly notes risks related to:
- Adverse and unpredictable macro-economic conditions.
- Risks associated with closing the acquisition and integrating the companies.
- The timing of the acquisition closing.
The Company disclaims any obligation to update these forward-looking statements.
Investor Verification Checklist
- Q3 2024 Financials: Review Exhibits 99.1 and 99.2 for specific revenue, net income, and cash flow figures not present in the 8-K text.
- Acquisition Terms: Verify the final closing date and any adjustments to the $43 million purchase price or share count.
- Related Party Transactions: Monitor the ongoing contract between Health Catalyst and The Queens Health System (QHS) given the new director's prior role as QHS CEO.
- Stock Dilution: Assess the impact of issuing approximately 2.2 million shares for the Intraprise acquisition on existing shareholders.